Abstract
Because of its capacity to neutralize the lethality of gram-negative bacterial endotoxic lipopolysaccharides, PMX-622 (polymyxin B bound to dextran 70) is being developed for possible adjunctive therapy of gram-negative sepsis. In this study, it was determined that the in vitro antimicrobial activity of PMX-622 was minimal and that it does not interfere with the in vitro antimicrobial activity of 11 antibiotics commonly used to treat gram-negative infections.
Highlights
Endotoxic lipopolysaccharides (LPS) of gram-negative bacteria have been implicated as a major factor contributing to mortality in patients with gram-negative sepsis [6]
The present study was designed to determine (i) the in vitro antimicrobial activity of PMX-622 against five species of gramnegative bacilli and (ii) the in vitro effect of PMX-622 on the antimicrobial activity of 11 antibiotics commonly used in the treatment of gram-negative bacterial infections
PMX-622 was provided by Sandoz Research Institute, East Hanover, N.J
Summary
Endotoxic lipopolysaccharides (LPS) of gram-negative bacteria have been implicated as a major factor contributing to mortality in patients with gram-negative sepsis [6]. The present study was designed to determine (i) the in vitro antimicrobial activity of PMX-622 against five species of gramnegative bacilli and (ii) the in vitro effect of PMX-622 on the antimicrobial activity of 11 antibiotics commonly used in the treatment of gram-negative bacterial infections. Clinical isolates of the following species were tested: 30 strains of Escherichia coli, 30 strains of Enterobacter cloacae, 32 strains of Klebsiella spp., strains of Pseudomonas aeruginosa, strains of Salmonella spp., and 5 strains of Staphylococcus aureus.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call